#1 Clinical Trials Search in Europe

Study on Denosumab for Improving Semen Quality in Men with Infertility

2 1 1

What is this study about?

This clinical trial is focused on studying male infertility, specifically a condition known as oligospermia, which is characterized by a low sperm count. The study aims to explore whether a medication called Denosumab can help improve the quality of semen in men who are experiencing infertility. Denosumab is administered as a solution for injection. Participants in the study will receive either Denosumab or a placebo, which is a substance with no active medication.

The purpose of the study is to determine if Denosumab can enhance sperm quality in men with reduced sperm production. Throughout the study, participants will receive injections and provide semen samples at specific intervals. The study will compare the sperm concentration and quality between those receiving Denosumab and those receiving the placebo. Additionally, the study will monitor changes in reproductive hormone levels, such as FSH (Follicle-Stimulating Hormone), LH (Luteinizing Hormone), AMH (Anti-Müllerian Hormone), and Inhibin B, which are important for understanding fertility health.

The study will also observe any differences in the occurrence of spontaneous pregnancies and any changes in the number of spontaneous abortions during the trial period. Participants will be followed over a period of time to assess these outcomes, with the final evaluation taking place at the end of the study. The results will help determine if Denosumab is effective in improving fertility in men with oligospermia.

1 initial visit

Upon joining the study, you will attend an initial visit. During this visit, your eligibility will be confirmed based on specific criteria, such as age and sperm concentration.

A blood sample will be taken to measure hormone levels, including AMH (anti-Müllerian hormone).

2 baseline semen sample

You will provide a semen sample to establish a baseline for sperm concentration and quality. This will help in comparing changes throughout the study.

3 medication administration

You will receive a subcutaneous injection of either Prolia (denosumab) or a placebo (saline). The injection will be administered under the skin using a pre-filled syringe.

The dosage for Prolia is 60 mg, and it will be given once at the start of the trial.

4 follow-up visits

You will attend follow-up visits to monitor your progress. These visits will include assessments of your health and any side effects you may experience.

Additional blood samples may be taken to measure hormone levels.

5 day 80 semen sample

On day 80, you will provide another semen sample. This sample will be used to evaluate changes in sperm concentration and quality compared to the baseline sample.

6 final assessments

At the end of the trial, final assessments will be conducted. These may include a review of any changes in reproductive hormones and overall semen quality.

The study will also track any spontaneous pregnancies and any changes in your health status.

Who Can Join the Study?

  • Must be a man.
  • Must be older than 18 years and younger than 60 years.
  • Must have reduced sperm production, which means having a sperm concentration of less than 2 million per milliliter.
  • Must have a serum AMH level greater than 30 pmol/L. AMH is a hormone that can be measured in the blood.

Who Cannot Join the Study?

  • Patients who are not male cannot participate.
  • Patients who are not within the specified age range cannot participate.
  • Patients who are part of a vulnerable population cannot participate. A vulnerable population includes groups who may have limited ability to give informed consent or are at higher risk of harm.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Hlsdrh Hrjrefai Herlev Denmark

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Denmark Denmark
Not recruiting
01.11.2023

Trial locations

Investigated drugs:

Denosumab is a medication that is being studied to see if it can help improve semen quality in men who have trouble with fertility. It works by affecting the bones and the cells that break down bone tissue. In this trial, researchers are exploring whether this medication can have a positive effect on sperm production and quality, which might help some men with fertility issues. The goal is to see if Denosumab can make a difference in the ability of these men to father children.

Investigated diseases:

Male infertility – Male infertility is a condition where a man has a reduced ability to father a child. It can result from various factors affecting sperm production, function, or delivery. The condition may involve low sperm production, abnormal sperm function, or blockages that prevent the delivery of sperm. As the condition progresses, it may lead to a decrease in sperm concentration and motility. Changes in reproductive hormone levels, such as FSH, LH, AMH, and Inhibin B, can also occur. These hormonal changes can further impact sperm quality and fertility potential.

Trial ID:
2023-508325-27-00
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study of vaginal pentoxifylline gel PKB171 compared to placebo in couples with mild male infertility due to low sperm count or poor sperm movement

    Recruiting

    4 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Follitropin Alfa and Chorionic Gonadotrophin for Men with Male Infertility, Low Testosterone, and Low Sperm Count

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Spain